What is the effect of durvalumab combined with tremelimumab/tremelimumab?

A combination of two immune checkpoint inhibitors, durvalumab and tremelimumab, is being considered for the treatment of different types of cancer. Tremelimumab is an IgG2 monoclonal antibody directed against cytotoxic T lymphocyte antigen-4 (CTLA-4) . It is used in combination with durvalumab, a monoclonal antibody directed against programmed cell death receptor ligand-1 (PD-L1), as an immunotherapy for hepatocellular carcinoma and non-small cell lung cancer.

Tremelimumab and durvalumab are both checkpoint inhibitors that work by inhibiting cellular pathways that downregulate immune responses, thereby helping to break tolerance and lead to immune clearance of cancer cells by promotingT cell activation and releasing cytotoxic anti-tumor activity. However, breaking tolerance can also lead to unintended immune-mediated damage to normal tissues. While immune checkpoint inhibitors (ICIs) have been used as immunotherapies to treat a variety of cancers, leading to long-term remissions in some patients, they can cause a range of long-term side effects.

Like other combinations of checkpoint protein, CTLA-4 and anti-PD-1 monoclonal antibody inhibitors, the combination of tremelimumab and imrvalumab has enhanced efficacy but also increases adverse events compared with either agent alone. The combination of tremelimumab and durvalumab has been shown to improve clinical response rates to chemotherapy in patients with many forms of advanced or metastatic cancer. The combination received accelerated approval in 2022 for the treatment of unresectable hepatocellular carcinoma and non-small cell lung cancer and continues to be evaluated as a treatment for other oncological diseases.

It was observed that the combination of tremelimumab and durvalumab was associated with a higher risk of discontinuation, mortality, pyrexia, diarrhea, rash, pruritus, and decreased appetite compared with durvalumab monotherapy. Side effects of treatment cannot be reliably attributed to one or the other drug, but long-term administration of durvalumab is likely to be responsible for most adverse events. Other serious adverse events with this combination include allergic reactions, tumor lysis syndrome, and embryo-fetal injury.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the price of each box of the US version of temsilimumaboriginal drug sold overseas may be At more than 3,000 US dollars, the specification is 300mg/50mL (20mg/mL), which is quite expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.